ZIB

Treffer pro Seite

Treffer 1 - 5 | 5 Treffer

Sortierung

Digitale Medien

Treatment of chronic myelogenous leukemia with interferons alpha and gamma (1990)

Kloke, O. ; May, D. ; Wandl, U. ; [weitere]

Springer

Annals of hematology 61 (1990), S. 45-46

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-0584

Schlagwort(e): Interferon alpha ; Interferon gamma ; Chronic myelogenous leukemia

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Notizen: Summary A 23-year-old male patient with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) was treated with both IFN alpha and IFN gamma. Normalization of leukocyte counts was reached after 3 months of treatment. Southern blot analysis failed to detect the neoplastic cell clone after 19 months of therapy. Cytogenetically, complete suppression of Ph positive cells in the patient's bone marrow and blood was observed after 20 months and 25 months, respectively. This response was achieved with doses of IFN alpha and IFN gamma which were considerably lower than the dosage of IFN used in single agent therapy of CML.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF01739433

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF α/IFN α therapy (1992)

Nagel-Hiemke, M. ; Hiemke, C. ; Kummer, G. ; [weitere]

Springer

Annals of hematology 65 (1992), S. 116-120

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-0584

Schlagwort(e): TNF α ; IFN α-2b ; Leukocytes ; Cortisol ; ACTH ; CML

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Notizen: Summary During long-term interferon α-2b (IFN) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients, short-term effects of tumor necrosis factor α (TNF) on peripheral leukocyte counts, as well as cortisol and corticotropin (ACTH) release were studied. TNF (40–160μg/m2) was given as a 2-h infusion on 5 consecutive days every 3 weeks, in addition to s.c. daily IFN injections (4 mio U/m2), to four (two male/two female) patients, who had been treated for more than 8 months with IFN and additionally for 0–7 months with TNF. Leukocyte counts, cortisol, and ACTH were determined at 30-min intervals between 4 p.m. and midnight. Profiles were determined the day before and on day 1 of TNF therapy. Leukocyte numbers decreased 30 min after start of TNF administration and increased 30–60 min later with a rebound until the next TNF application. The increase of leukocyte counts was due mostly to neutrophil granulocytes. ACTH levels increased 30 min, cortisol 60 min, and leukocyte counts 90 min after start of TNF infusion. Metopirone, an inhibitor of cortisol synthesis given to one patient, suppressed the TNF-induced stimulation of cortisol secretion and subsequent increase of leukocyte counts, while ACTH blood levels were enhanced. It was concluded that leukocyte count increases after TNF/IFN administration might be related to TNF-evoked cortisol secretion.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF01695809

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study (1991)

Niederle, N. ; Ostermann, J. ; Achterrath, W. ; [weitere]

Springer

Cancer chemotherapy and pharmacology 28 (1991), S. 59-62

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-0843

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Notizen: Summary In a phase I study, a range of doses of etoposide (200–370 mg/m2 given i. v. daily on 3 consecutive days) were evaluated for tolerance and response as first-line treatment in 26 patients with non-small-cell lung cancer. The dose-limiting toxicity was myelosuppression, especially leukopenia. At dose levels of 350 and 370 mg/m2 ctoposide per day, leukopenia of WHO grade 4 occurred in two and one of seven patients, respectively. No thrombocytopenia of this degree was observed. Myelosuppression was quickly reversible and noncumulative. Apart from alopecia, nonhematologic organ toxicities above WHO grade 2 were not seen. Toxicity analysis suggests that the recommended dose of single-agent etoposide for phase II studies in untreated patients is 330–370 mg/m2 given i. v. daily for 3 days. At the dose levels tested, 6 (23%) major responses could be induced. All responses were seen at a starting dose of 〉300 mg/m2 per day. The median duration of response was 4 months. The median survival for all patients was 8 months and that for responding patients was 15 months.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00684958

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

Metastasierender Leydig-Zell-Tumor des Hodens mit einem Markerenzym (1979)

Higi, M. ; Niederle, N. ; Scheulen, M. E. ; [weitere]

Springer

Journal of cancer research and clinical oncology 94 (1979), S. 325-331

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-1335

Schlagwort(e): Interstitial cell tumor of testis ; Metastases ; Case report ; Alkaline phosphatase ; Hormonal dysfunction ; Chemotherapy ; Metastasierender Leydig-Zell-Tumor des Hodens ; Fallbericht ; Alkalische Phosphatase ; Hormonelle Dysfunktion ; Chemotherapie

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Beschreibung / Inhaltsverzeichnis: Zusammenfassung Der metastasierende Leydig-Zell-Tumor des Hodens gehört zu den seltensten menschlichen Neoplasien. Bisher sind 18 Fälle beschrieben worden. Die Mehrzahl dieser Tumoren zeigt hormonelle Aktivitäten. Der von uns beobachtete maligne Leydig-Zell-Tumor weist neben einem ungewöhnlichen Hormonprofil zusätzlich ein Markerenzym — die alkalische Phosphatase — auf. Bei fehlender Radiosensibilität wurde auch mit neueren cytostatischen Substanzen kein Therapieerfolg erreicht. Weniger als 10% aller Leydig-Zell-Tumoren erfüllen die Kriterien der Malignität. Achtzehn Fallbeschreibungen der malignen Form liegen unseres Wissens bisher vor. Wir berichten über einen weiteren Patienten mit histologisch gesichertem Laydig-Zell-Tumor, den klinischen Verlauf, die therapeutischen Erfahrungen mit neueren cytostatischen Substanzen sowie die Besonderheit eines Enzym-Markers.

Notizen: Summary Metastatic interstitial cell tumor of the testis is one of the rarest human neoplasms. This is the nineteenth case to be reported. While most of these tumors are combined with hormonal dysfunction, the present tumor, apart from its uncommon hormonal profile, is remarkable because of its capacity of producing and secreting a marker enzyme, alkaline phosphatase. No response was seen after cytostatic therapy with new antineoplastic agents, such as a combination of adriamycin and cis-diamminedichlorideplatinum (II), and ifosfamide. Considering the lack of radiosensitivity, surgery is the primary modality of treatment.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00419291

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

The concept of dose intensification in the treatment of neoplastic disease (1992)

Wandl, Ursula B. ; Niederle, N.

Springer

Infection 20 (1992), S. S107

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1439-0973

Quelle: Springer Online Journal Archives 1860-2000

Thema: Medizin

Beschreibung / Inhaltsverzeichnis: Zusammenfassung In der vorliegenden Arbeit werden unterschiedliche theoretische und klinische Ansätze, die zu dem Konzept der Dosisintensivierung beigetragen haben, beschrieben. Dieses Konzept beinhaltet, daß die Dosierungen von verabreichten Zytostatika pro Zeiteinheit mitbestimmend für die erfolgreiche Behandlung von Patienten mit malignen Tumorerkrankungen sind. Durch den klinischen Einsatz von rekombinanten hämatopoetischen Wachstumsfaktoren können Nebenwirkungen auf das Knochenmark verringert werden, so daß das Konzept der Dosisintensivierung klinisch besser realisierbar wird. Prospektive randomisierte Studien, bei denen nur die Dosis-Intensität verändert wird, werden vermehrt erforderlich. Es wird sich dann erweisen, ob die Dosisintensivierung zu einer Lebensverlängerung beitragen kann.

Notizen: Summary This paper summarizes different theoretical and clinical approaches contributing to the concept of dose intensification. According to this concept, the amount of antineoplastic drug delivered per time predominantly determines the clinical outcome in patients with neoplastic disease. With the availability of recombinant haemopoietic growth factors haematotoxic side effects might be reduced, making this concept more feasible for clinical use. However, more prospective randomized studies, in which dose-intensity is the only treatment variable, are needed to prove that dose intensification will lead to higher survival rates.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF01705028

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Treffer 1 - 5 | 5 Treffer